Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model

Ha-Na Leea Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USAView further author information

Ian L. McWilliamsa Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USAView further author information

Aaron P. Lewkowicza Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USAView further author information

Kaliroi Engela Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USAView further author information

Derek D. C. Irelanda Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USAView further author information

Logan Kelley-Bakera Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USAView further author information

Seth Thackera Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USAView further author information

Pedro Piccardob Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USAView further author information

Mohanraj Manangeeswarana Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USACorrespondence[email protected] [email protected]
View further author information

Daniela Verthelyia Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USACorrespondence[email protected] [email protected]

https://orcid.org/0000-0002-5450-3071 View further author information

show all

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date